162 related articles for article (PubMed ID: 12102577)
1. The emerging role of angiogenesis inhibitors in hematologic malignancies.
Giles FJ
Oncology (Williston Park); 2002 May; 16(5 Suppl 4):23-9. PubMed ID: 12102577
[TBL] [Abstract][Full Text] [Related]
2. The vascular endothelial growth factor (VEGF) signaling pathway: a therapeutic target in patients with hematologic malignancies.
Giles FJ
Oncologist; 2001; 6 Suppl 5():32-9. PubMed ID: 11700390
[TBL] [Abstract][Full Text] [Related]
3. [Angiogenesis and hematologic malignancy].
Zini JM; Tobelem G
Bull Cancer; 2007 Jul; 94 Spec No():S241-6. PubMed ID: 17846010
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of vascular endothelial growth factor-associated tyrosine kinase activity with SU5416 blocks sprouting in the microvascular endothelial cell spheroid model of angiogenesis.
Haspel HC; Scicli GM; McMahon G; Scicli AG
Microvasc Res; 2002 May; 63(3):304-15. PubMed ID: 11969307
[TBL] [Abstract][Full Text] [Related]
5. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
[TBL] [Abstract][Full Text] [Related]
6. Role of angiogenesis inhibitors in acute myeloid leukemia.
Fiedler W; Staib P; Kuse R; Dührsen U; Flasshove M; Cavalli F; Hossfeld DK; Berdel WE
Cancer J; 2001; 7 Suppl 3():S129-33. PubMed ID: 11779083
[TBL] [Abstract][Full Text] [Related]
7. Role of VEGF/VEGFR in the pathogenesis of leukemias and as treatment targets (Review).
Song G; Li Y; Jiang G
Oncol Rep; 2012 Dec; 28(6):1935-44. PubMed ID: 22993103
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
Wood JM
Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
[TBL] [Abstract][Full Text] [Related]
9. Angiogenesis in acute and chronic leukemias.
Dickson DJ; Shami PJ
Leuk Lymphoma; 2001; 42(5):847-53. PubMed ID: 11697639
[TBL] [Abstract][Full Text] [Related]
10. [Angiogenesis in patients with hematologic malignancies].
Mesters RM; Padró T; Steins M; Bieker R; Retzlaff S; Kessler T; Kienast J; Berdel WE
Onkologie; 2001 Sep; 24 Suppl 5():75-80. PubMed ID: 11600818
[TBL] [Abstract][Full Text] [Related]
11. Taxotere and vincristine inhibit the secretion of the angiogenesis inducing vascular endothelial growth factor (VEGF) by wild-type and drug-resistant human leukemia T-cell lines.
Avramis IA; Kwock R; Avramis VI
Anticancer Res; 2001; 21(4A):2281-6. PubMed ID: 11724283
[TBL] [Abstract][Full Text] [Related]
12. A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma.
Vacca A; Ria R; Ribatti D; Semeraro F; Djonov V; Di Raimondo F; Dammacco F
Haematologica; 2003 Feb; 88(2):176-85. PubMed ID: 12604407
[TBL] [Abstract][Full Text] [Related]
13. Anti-VEGF antibody in experimental hepatoblastoma: suppression of tumor growth and altered angiogenesis.
McCrudden KW; Hopkins B; Frischer J; Novikov A; Huang J; Kadenhe A; New T; Yokoi A; Yamashiro DJ; Kandel JJ; Middlesworth W
J Pediatr Surg; 2003 Mar; 38(3):308-14; discussion 308-14. PubMed ID: 12632340
[TBL] [Abstract][Full Text] [Related]
14. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies.
Bellamy WT; Richter L; Frutiger Y; Grogan TM
Cancer Res; 1999 Feb; 59(3):728-33. PubMed ID: 9973224
[TBL] [Abstract][Full Text] [Related]
15. Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer.
Zhang L; Yang N; Park JW; Katsaros D; Fracchioli S; Cao G; O'Brien-Jenkins A; Randall TC; Rubin SC; Coukos G
Cancer Res; 2003 Jun; 63(12):3403-12. PubMed ID: 12810677
[TBL] [Abstract][Full Text] [Related]
16. Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia.
Ebos JM; Tran J; Master Z; Dumont D; Melo JV; Buchdunger E; Kerbel RS
Mol Cancer Res; 2002 Dec; 1(2):89-95. PubMed ID: 12496355
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia.
Padró T; Bieker R; Ruiz S; Steins M; Retzlaff S; Bürger H; Büchner T; Kessler T; Herrera F; Kienast J; Müller-Tidow C; Serve H; Berdel WE; Mesters RM
Leukemia; 2002 Jul; 16(7):1302-10. PubMed ID: 12094254
[TBL] [Abstract][Full Text] [Related]
18. Role of tumour angiogenesis in haematological malignancies.
Medinger M; Passweg J
Swiss Med Wkly; 2014; 144():w14050. PubMed ID: 25375891
[TBL] [Abstract][Full Text] [Related]
19. Vascular endothelial growth factor signaling pathway as an emerging target in hematologic malignancies.
List AF
Oncologist; 2001; 6 Suppl 5():24-31. PubMed ID: 11700389
[TBL] [Abstract][Full Text] [Related]
20. Angiogenesis and angiogenic mediators in haematological malignancies.
Mangi MH; Newland AC
Br J Haematol; 2000 Oct; 111(1):43-51. PubMed ID: 11091181
[No Abstract] [Full Text] [Related]
[Next] [New Search]
